-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Quoin Pharmaceuticals (NASDAQ:QNRX) Shares Down 2.4%
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
Get Quoin Pharmaceuticals alerts:Quoin Pharmaceuticals Stock Performance
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
Quoin Pharmaceuticals (NASDAQ:QNRX – Get Rating) last released its earnings results on Monday, May 23rd. The company reported ($2.50) earnings per share for the quarter. On average, equities analysts anticipate that Quoin Pharmaceuticals, Ltd. will post -6.5 EPS for the current fiscal year.Institutional Investors Weigh In On Quoin Pharmaceuticals
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
Quoin Pharmaceuticals Company Profile
(Get Rating)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Read More
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) fell 2.4% during mid-day trading on Wednesday . The stock traded as low as $4.45 and last traded at $4.98. 7,351,853 shares traded hands during mid-day trading, an increase of 1,036% from the average session volume of 646,993 shares. The stock had previously closed at $5.10.
納斯達克股票代碼:QNRX-GET評級週三午盤下跌2.4%。該股一度跌至4.45美元,最後報4.98美元。午盤成交量為7,351,853股,較646,993股的平均成交量增加1,036%。該股此前收盤價為5.10美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several brokerages recently issued reports on QNRX. LADENBURG THALM/SH SH began coverage on Quoin Pharmaceuticals in a research note on Friday, May 6th. They issued a "buy" rating and a $25.00 price target for the company. Maxim Group cut their price target on Quoin Pharmaceuticals to $25.00 in a research note on Thursday, May 26th.
幾家券商最近發佈了關於QNRX的報告。拉登堡THALM/SH SH在5月6日星期五的一份研究報告中開始報道Quoin PharmPharmticals。他們對該公司的評級為“買入”,目標價為25美元。Maxim Group在5月26日星期四的一份研究報告中將Quoin PharmPharmticals的目標價下調至25.00美元。
Quoin Pharmaceuticals Stock Performance
Quoin製藥類股表現
The firm has a 50 day simple moving average of $6.04 and a two-hundred day simple moving average of $11.38.
該公司的50日簡單移動均線切入位在6.04美元,200日簡單移動均線切入位在11.38美元。
Institutional Investors Weigh In On Quoin Pharmaceuticals
機構投資者看好Quoin製藥公司
An institutional investor recently bought a new position in Quoin Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX – Get Rating) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,665 shares of the company's stock, valued at approximately $57,000. Virtu Financial LLC owned about 0.51% of Quoin Pharmaceuticals at the end of the most recent reporting period. Institutional investors own 21.72% of the company's stock.
一家機構投資者最近買入了Quoin PharmPharmticals股票的新頭寸。根據Virtu Financial LLC最近提交給美國證券交易委員會的13F文件,該公司在第一季度購買了Quoin PharmPharmticals,Ltd.(納斯達克代碼:QNRX-GET Rating)的新股票頭寸。該機構投資者購買了42,665股該公司股票,價值約57,000美元。在最近的報告期結束時,Virtu Financial LLC擁有Quoin製藥公司約0.51%的股份。機構投資者持有該公司21.72%的股份。
Quoin Pharmaceuticals Company Profile
Quoin製藥公司簡介
(Get Rating)
(獲取評級)
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease.
Quoin PharmPharmticals,Ltd.是一家專業製藥公司,專注於開發治療罕見和孤兒疾病的產品。該公司的主導產品是QRX003,一種治療Netherton綜合徵的外用洗劑。它還開發了用於治療營養不良性大皰性表皮鬆解症的QRX004;以及治療罕見皮膚病的QRX006。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Quoin Pharmaceuticals (QNRX)
- Large And Small Oil-And-Gas Stocks See Post-Earnings Bounce
- The 2 Dow Stocks with Decade-Long Win Streaks on the Line
- Could Rite Aid Be an Acquisition Target, Again?
- The How And Why of Investing in Oil Stocks
- The How and Why of Investing in Gold Stocks
- 免費獲取StockNews.com關於Quoin PharmPharmticals的研究報告(QNRX)
- 大型和小型石油和天然氣類股盈利後反彈
- 連續十年上漲的兩隻道指股票
- Rite Aid會再次成為收購目標嗎?
- 投資石油股票的方式和原因
- 投資黃金股票的方式和原因
Receive News & Ratings for Quoin Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quoin Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Quoin PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Quoin製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧